ELICIO THERAPEUTICS ELTX 深 沪
已收盘 08-08 16:00:00 美东时间
9.20
+0.130
+1.43%
华盛通- 最 高9.52
- 今 开9.35
- 成交量 2.48万股
- 最 低 9.0612
- 昨 收 9.07
- 总市值 1.47亿
- 52周最高 10.75
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 3.70
- 委 比 -81.82%
- 总股本 1599.70万
- 历史最高 263.00
- 量 比 0.81
- 振 幅 5.06%
- 历史最低 2.96
- 每 手 1
- 风险率 1.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Elicio Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 3.13 percent decrease over losses of $(0.64) per share
08-08 04:37
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
<p>Elicio Therapeutics reported positive updates on its Phase 2 study for pancreatic cancer, securing $10 million in financing, and detailed its financial results. The IDMC recommended continuing the ELI-002 7P trial without modifications, with final data expected in Q4 2025.</p>
08-07 20:30
Elicio's Pancreatic Cancer Vaccine Trial Clears Key Review, Moves Ahead Without Changes
Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that following the
08-05 19:11
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
Elicio Therapeutics announced that the IDMC has recommended continuing its Phase 2 AMPLIFY-7P study of ELI-002 7P for mKRAS-driven pancreatic cancer without modifications, citing favorable safety and preliminary efficacy signals. The trial aims to improve disease-free survival (DFS) in high-risk patients. The final DFS analysis is expected in Q4 2025, with plans for an End-of-Phase 2 meeting with the FDA. Elicio's cash runway extends into Q1 2026...
08-05 11:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers OSR Holdings (NASDAQ:OSRH) stock rose 21.4% to $1.05 during Wednesday'...
07-31 05:06
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $13
HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $10 to $13.
07-17 18:34
Elicio Therapeutics To Host June 25 Virtual KOL Event At 2:00 PM ET Highlighting Urgent Need And Phase 2 Progress Of AMP-Powered ELI-002 Vaccine For mKRAS-Driven Pancreatic Cancer
Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a
06-17 20:09
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
Elicio Therapeutics将于2025年6月25日举办一场关于mKRAS驱动胰腺导管腺癌（PDAC）治疗的虚拟关键意见领袖（KOL）活动。活动将邀请两名顶尖专家参与，并重点讨论Elicio公司的淋巴结靶向两亲聚合物（AMP）平台及其主导产品ELI-002。ELI-002是一种基于AMP技术的治疗性疫苗，目前处于针对mKRAS驱动PDAC的随机2期临床试验阶段。活动还预计将涵盖AMP平台的优势及其在克服免疫逃逸方面的潜力。
06-17 12:00
Elicio Therapeutics secures $10M in financing
Elicio Therapeutics (NASDAQ:ELTX) has entered a $10M senior secured promissory note with existing investor, GKCC. The proceeds from the Note Financing, together with Elicio’s current cash and equivale...
06-04 20:03
Elicio Therapeutics Secures $10 Million in Financing
Elicio Therapeutics与现有投资者GKCC达成1000万美元高级担保票据融资协议，支持运营至2026年第一季度，包括2025年第三季度的AMPLIFY-7P二期中期分析。融资包括12.5%利率、2028年到期、24个月只付息期及认股权证，以增强财务灵活性，推进PDAC和CRC中的ELI-002组合疗法开发，巩固其AMP免疫技术平台。
06-04 12:00
